BDSX
Biodesix Inc

1,703
Mkt Cap
$82.74M
Volume
41,150.00
52W High
$20.40
52W Low
$3.44
PE Ratio
-1.94
BDSX Fundamentals
Price
$10.06
Prev Close
$10.40
Open
$10.36
50D MA
$8.35
Beta
0.50
Avg. Volume
4.21M
EPS (Annual)
-$6.62
P/B
-48.04
Rev/Employee
$261,256.41
$234.03
Loading...
Loading...
News
all
press releases
Biodesix, Inc. (NASDAQ:BDSX) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) have been given an average rating of "Moderate Buy" by the six research firms that are covering the company, MarketBeat.com reports. One...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Biodesix (NASDAQ:BDSX) Director Acquires $236,000.00 in Stock
Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) Director Jack Schuler acquired 20,000 shares of the firm's stock in a transaction that occurred on Monday, January 26th. The shares were bought at an...
MarketBeat·15d ago
News Placeholder
Biodesix (NASDAQ:BDSX) Director Jack Schuler Purchases 80,000 Shares
Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) Director Jack Schuler acquired 80,000 shares of the business's stock in a transaction dated Friday, January 23rd. The stock was acquired at an average...
MarketBeat·15d ago
News Placeholder
Insider Buying: Biodesix (NASDAQ:BDSX) Director Acquires 82,465 Shares of Stock
Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) Director Jack Schuler bought 82,465 shares of the firm's stock in a transaction dated Thursday, January 22nd. The shares were acquired at an average...
MarketBeat·15d ago
News Placeholder
Biodesix (NASDAQ:BDSX) Director Jack Schuler Buys 82,465 Shares
Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) Director Jack Schuler acquired 82,465 shares of the stock in a transaction that occurred on Thursday, January 22nd. The shares were acquired at an...
MarketBeat·16d ago
News Placeholder
Perkins Capital Management Inc. Has $397,000 Position in Biodesix, Inc. $BDSX
Perkins Capital Management Inc. lessened its position in shares of Biodesix, Inc. (NASDAQ:BDSX - Free Report) by 95.0% in the third quarter, according to the company in its most recent 13F filing...
MarketBeat·16d ago
News Placeholder
Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Rating of "Moderate Buy" by Brokerages
Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the six brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the...
MarketBeat·26d ago
News Placeholder
BDSX Stock Shot Up 23% Pre-Market Today — What’s Fueling The Surge?
The company expects Q4 revenue of $28.8 million, a 41% year-over-year increase, while full-year revenue is estimated at $88.5 million, up 24% year-over-year.
Stocktwits·1mo ago
News Placeholder
SOLV Acquires Acera Surgical to Expand Advanced Wound Care Portfolio
Solventum buys Acera Surgical for $725M upfront to enter tissue matrices, expanding MedSurg and wound care.
Zacks·2mo ago
News Placeholder
Biodesix, Inc. (NASDAQ:BDSX) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) have received a consensus rating of "Moderate Buy" from the six brokerages that are covering the stock, MarketBeat.com reports. One analyst...
MarketBeat·2mo ago
<
1
2
...
>

Latest BDSX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.